Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

HEALIUS LIMITED Capital/Financing Update 2018

Sep 13, 2018

65058_rns_2018-09-13_d470c1dd-eaf1-4fbd-9c17-1cd9be3759cc.pdf

Capital/Financing Update

Open in viewer

Opens in your device viewer

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

PRIMARY HEALTH CARE LIMITED

ABN

24 064 530 516

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

1 +Class of +securities issued or to Fully paid ordinary shares (“ Shares ”). be issued

  • See chapter 19 for defined terms.

Appendix 3B Page 1

04/03/2013

2 Number of[+] securities issued or 100,182,944 Shares issued pursuant to the to be issued (if known) or accelerated non‐renounceable pro rata maximum number which may entitlement offer as detailed in the ASX be issued announcement dated 20 August 2018 (“ Entitlement Offer ”). This total comprises:  37,692,926 Shares issued pursuant to the retail component of the Entitlement Offer; and  62,490,018 Shares issued pursuant to the institutional component of the Entitlement Offer. This Appendix 3B updates the approximate number of ordinary shares to be issued under the Entitlement Offer as detailed in the Appendix 3Bs issued on 20 August 2018 and 28 August 2018.

  • 3 Principal terms of the Fully paid ordinary shares issued for cash +securities (e.g. if options, consideration. exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)

4 Do the[+] securities rank equally From the issue date, the Shares will rank in all respects from the[+] issue equally in all respects with the existing fully date with an existing[+] class of paid ordinary shares in Primary currently on quoted[+] securities? issue. However, the Shares will not be entitled to the FY2018 final dividend. If the additional[+] securities do not rank equally, please state:  the date from which they do  the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 5 Issue price or consideration $2.50 per Share 6 Purpose of the issue The purpose of the Offer is to fund strategic (If issued as consideration for growth initiatives and an acquisition, as the acquisition of assets, clearly disclosed in the Announcements to ASX identify those assets) dated 20 August 2018 and 10 September 2018. 6a Is the entity an[+] eligible entity No. that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b – 6h in relation to the[+] securities the subject of this Appendix 3B , and comply with section 6i 6b The date the security holder N/A resolution under rule 7.1A was passed 6c Number of[+] securities issued N/A without security holder approval under rule 7.1 6d Number of[+] securities issued N/A with security holder approval under rule 7.1A

  • See chapter 19 for defined terms.

Appendix 3B Page 3

04/03/2013

6e
Number of+securities issued
with security holder approval
under rule 7.3, or another
specific security holder approval
(specify date of meeting)
6f
Number of+securities issued
under an exception in rule 7.2
6g
If+securities issued under rule
7.1A, was issue price at least 75%
of 15 day VWAP as calculated
under rule 7.1A.3? Include the
+issue date and both values.
Include the source of the VWAP
calculation.
6h
If+securities were issued under
rule
7.1A
for
non‐cash
consideration, state date on
which
valuation
of
consideration was released to
ASX Market Announcements
6i
Calculate the entity’s remaining
issue capacity under rule 7.1 and
rule 7.1A – complete Annexure 1
and release to ASX Market
Announcements
7
+Issue dates
Note: The issue date may be prescribed by
ASX (refer to the definition of issue date in
rule 19.12). For example, the issue date for a
pro rata entitlement issue must comply with
the applicable timetable in Appendix 7A.
Cross reference: item 33 of Appendix 3B.
N/A
N/A

N/A
N/A
N/A
The issue date for Shares under the
institutional component of the Entitlement
Offer was 29 August 2018.
The issue date for Shares under the retail
component of the Entitlement Offer is 14
September 2018.
  • 8 Number and +class of all +securities quoted on ASX ( including the +securities in section 2 if applicable)

  • 9 Number and +class of all +securities not quoted on ASX ( including the +securities in section 2 if applicable)

Number Number +Class
622,104,554 Fully paid
ordinary shares
Number +Class
477,500–
150,000
(lapsed/expired)
Options
327,500 Total current
unlisted Options
92,728
126,907
131,190
FY16 Employee Service
Rights vesting after
30.06.2018 (subject to
plan
rules)
FY17 Employee Service
Rights vesting after
30.06.2018 (subject to
plan rules)
FY17 Employee Service
Rights vesting after
01.09.2019 (subject to
plan rules)
350,825 Total current
unlisted Employee
Service Rights
2,294,896
2,762,960
FY16 Employee
Performance Rights
vesting after 01.09.2019
(subject to plan rules)
FY17 Employee
Performance Rights
vesting after 30.06.2020
(subject toplan rules)
5,057,856 Total current
unlisted Employee
Performance Rights

10 Dividend policy (in the case of a The Shares issued under the Entitlement trust, distribution policy) on the Offer will not participate in the FY18 full increased capital (interests) year dividend, but will be entitled to distributions for any future period.

  • See chapter 19 for defined terms.

Appendix 3B Page 5

04/03/2013

Part 2 - Pro rata issue

11
Is
security
holder
approval
required?
12
Is the issue renounceable or non‐
renounceable?
13
Ratio in which the+securities
will be offered
14
+Class of+securities to which the
offer relates
15
+Record
date
to
determine
entitlements
16
Will
holdings
on
different
registers (or subregisters) be
aggregated
for
calculating
entitlements?
17
Policy for deciding entitlements
in relation to fractions
18
Names of countries in which the
entity has security holders who
will not be sent new offer
documents
Note: Security holders must be told how their
entitlements are to be dealt with.
Cross reference: rule 7.7.
19
Closing
date
for
receipt
of
acceptances or renunciations
No.
Non‐renounceable.
1 new Share for every 5.21 Shares held at the
record date
Fully paid ordinary shares.
7.00pm (Sydney time) on 22 August 2018.
No.
Where fractions arose in the calculation of
shareholders’
entitlements
under
the
Entitlement Offer, they were rounded up
to the nearest whole number.
For
the
retail
component
of
the
Entitlement Offer, all countries other than
Australia and New Zealand.
For the institutional component of the
Entitlement Offer, all countries other than
Australia, New Zealand, Canada (Quebec,
Ontario and British Columbia), China,
Denmark, France, Germany, Hong Kong,
Ireland, Italy, Luxembourg, Netherlands,
Norway,
Singapore,
Spain,
Sweden,
Switzerland, the United Kingdom and
Virgin Islands.
The
institutional
component
of
the
Entitlement Offer closed on 21 August
2018.
The retail component of the Entitlement
Offer closed on7September 2018.
20
Names of any underwriters
21
Amount of any underwriting fee
or commission
22
Names of any brokers to the
issue
23
Fee or commission payable to
the broker to the issue
24
Amount of any handling fee
payable to brokers who lodge
acceptances or renunciations on
behalf of security holders
25
If the issue is contingent on
security holders’ approval, the
date of the meeting
26
Date entitlement and acceptance
form and offer documents will be
sent to persons entitled
Morgan
Stanley
Australia
Securities
Limited
UBS AG,Australia Branch
Primary
has
agreed
to
pay
each
Underwriter an equal proportion of the
following fees:

an underwriting fee of 1.45% of the
Institutional
Entitlement
Offer
component;

an underwriting fee of 1.45% of the
Retail
Entitlement
Offer
component; and

a management and selling fee of
0.4%
of
the
Institutional
Entitlement Offer component;

a management and selling fee of
0.4% of the Retail Entitlement
Offer component; and

at
the
absolute
discretion
of
Primary, an incentive fee of up to
0.2% of the aggregate of the
Institutional Offer and Retail Offer
components.
N/A
N/A
N/A
N/A
No prospectus was produced. A Retail
Offer
Booklet
and
Entitlement
and
Acceptance Form was sent to eligible retail
shareholders on 27 August 2018. An
investor presentation dated 20 August 2018
has beenprovided to the ASX.
  • See chapter 19 for defined terms.

Appendix 3B Page 7

04/03/2013

27 If the entity has issued options, N/A and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders 28 Date rights trading will begin (if N/A applicable) 29 Date rights trading will end (if N/A applicable) 30 How do security holders sell N/A their entitlements in full through a broker? 31 How do security holders sell part N/A of their entitlements through a broker and accept for the balance? 32 How do security holders dispose N/A of their entitlements (except by sale through a broker)? 33 +Issue date The issue date for Shares under the institutional component of the Entitlement Offer was 29 August 2018. The issue date for Shares under the retail component of the Entitlement Offer is 14 September 2018.

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

  • 34 Type of[+] securities ( tick one )

  • (a) +Securities described in Part 1

  • (b) All other[+] securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

35 If the[+] securities are[+] equity securities, the names of the 20 largest holders of the additional[+] securities, and the number and percentage of additional[+] securities held by those holders 36 If the[+] securities are[+] equity securities, a distribution schedule of the additional +securities setting out the number of holders in the categories 1 ‐ 1,000 1,001 ‐ 5,000 5,001 ‐ 10,000 10,001 ‐ 100,000 100,001 and over 37 A copy of any trust deed for the additional[+] securities

Entities that have ticked box 34(b)

38
Number of+securities for which
+quotation is sought
39
+Class of+securities for which
quotation is sought
40
Do the+securities rank equally in
all respects from the+issue date
with an existing+class of quoted
+securities?
If the additional+securities do
not rank equally, please state:
 the date from which they do
 the extent to which they
participate
for
the
next
dividend, (in the case of a
trust, distribution) or interest
payment
 the extent to which they do
not rank equally, other than in
relation to the next dividend,
distribution
or
interest
payment
N/A
N/A
N/A
  • See chapter 19 for defined terms.

Appendix 3B Page 9

04/03/2013

41 Reason for request for quotation N/A now Example: In the case of restricted securities, end of restriction period (if issued upon conversion of another[+] security, clearly identify that other[+] security)

Number +Class 42 Number and +class of all N/A N/A +securities quoted on ASX ( including the +securities in clause 38)

Quotation agreement

  • 1 +Quotation of our additional +securities is in ASX’s absolute discretion. ASX may quote the[+] securities on any conditions it decides.

  • 2 We warrant the following to ASX.

  • The issue of the[+] securities to be quoted complies with the law and is not for an illegal purpose.

  • There is no reason why those[+] securities should not be granted +quotation.

  • An offer of the[+] securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

  • Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any[+] securities to be quoted and that no‐one has any right to return any[+] securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the[+] securities be quoted.

  • If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the[+] securities be quoted.

  • 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

  • 4 We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: ................................................... Date: 14 September 2018 Company secretary

Print name: CHARLES TILLEY

== == == == ==

  • See chapter 19 for defined terms.

Appendix 3B Page 11

04/03/2013